LGND Stock News & Catalysts – Ligand Pharmaceuticals

FEATURED

Ligand Reports Third Quarter 2026 Financial Results

Third-quarter royalty revenue up 51% year-over-year to $70.3 million Raises Full-Year 2026 Adjusted Diluted EPS Guidance to $9.50 to $9.75, from $9.00 to $9.501; Reaffirms Revenue Guidance Conference call begins at

Summary

Oct 29, 2026, 7:00 AM ·Globe Newswire

RECENT

Ligand to Participate in November Investor Conferences

JUPITER, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its senior management team will participate in the following upcoming investor conferences: UBS

Oct 27, 2026, 4:01 PM ·Globe Newswire

Ligand to Host Investor Day on December 8, 2026

JUPITER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its annual Investor Day will take place on Tuesday, December 8, 2026 from 10:30 a.m. to 12:00

Oct 22, 2026, 4:01 PM ·Globe Newswire

Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026

JUPITER, Fla., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report third quarter 2026 financial results on Thursday, October 29, 2026. The company

Oct 15, 2026, 7:00 AM ·Globe Newswire

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage

Sep 24, 2026, 7:00 AM ·Globe Newswire

Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®

$23 million upfront payment immediately monetizes future royalties associated with Ryjunea in Europe, the Middle East, and Africa Capital further strengthens Sydnexis’ balance sheet as Company continues to advance

Sep 22, 2026, 9:02 AM ·Business Wire

Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners

SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by new investor

Sep 22, 2026, 9:00 AM ·PRNewswire

Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million

Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients Ligand will receive a tiered low-double-digit to high-teens royalty

Sep 22, 2026, 7:00 AM ·Globe Newswire

Ligand to Participate in September Investor Conferences

JUPITER, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced its senior management team will participate in the following upcoming investor conferences: Wells

Aug 26, 2026, 7:00 AM ·Globe Newswire

Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

The BACKBEAT global pivotal trial ("BACKBEAT Trial"), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data

Aug 10, 2026, 4:12 PM ·Globe Newswire

Ligand Reports Second Quarter 2026 Financial Results

Second quarter performance driven by strong year-over-year royalty revenue growth of 32% Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged Conference call begins at 8:30 a.m. Eastern Time today

Aug 6, 2026, 7:00 AM ·Globe Newswire

Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026

JUPITER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026. The company

Jul 23, 2026, 7:00 AM ·Globe Newswire

XOMA Royalty Announces Closing of Its Acquisition by Ligand

EMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has completed its previously announced acquisition of XOMA Royalty.

Jul 14, 2026, 9:00 AM ·Globe Newswire

Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets

Acquisition adds seven commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and more than 100 development and commercial-stage assets, creating long-term

Jul 14, 2026, 9:00 AM ·Globe Newswire

Ligand Announces Closing of Convertible Senior Notes Offering

Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution

Jun 25, 2026, 4:01 PM ·Globe Newswire

Ligand Pharmaceuticals Incorporated LGND · News